Recent Advances and Perspectives in Relation to the Metabolomics-Based Study of Diabetic Retinopathy

Metabolites. 2023 Sep 12;13(9):1007. doi: 10.3390/metabo13091007.

Abstract

Diabetic retinopathy (DR), a prevalent microvascular complication of diabetes, is a major cause of acquired blindness in adults. Currently, a clinical diagnosis of DR primarily relies on fundus fluorescein angiography, with a limited availability of effective biomarkers. Metabolomics, a discipline dedicated to scrutinizing the response of various metabolites within living organisms, has shown noteworthy advancements in uncovering metabolic disorders and identifying key metabolites associated with DR in recent years. Consequently, this review aims to present the latest advancements in metabolomics techniques and comprehensively discuss the principal metabolic outcomes derived from analyzing blood, vitreous humor, aqueous humor, urine, and fecal samples.

Keywords: biomarker; diabetic retinopathy; metabolic pathway; metabolomics.

Publication types

  • Review

Grants and funding

This study was funded by the Natural Science Foundation of Fujian Province (grant no. 2022J01236).